#$%^&*AU2016238842A120161027.pdf#####METHOD FOR DETERMINING CLINICALLY RELEVANT HYPOXIA IN CANCER Abstract The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD1 1 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 0 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.
